Has it already been a year?

Avedro (maker of the FDA approved corneal cross-linking system) announced the one year results from their phase 3 clinical trial.
The summary?
At the 12 month follow up, they found:

  • Steep K values decreased by 1.6D.
  • Visual acuity improved by 5.5 letters.
  • Adverse events were reported in 5 eyes (out of 205). They were persistent corneal haze in 2 eyes, corneal scar in 1 eye, endothelial folds in 1 eye, and irregular corneal epithelium in 1 eye.

The authors state, “this trial demonstrated the efficacy and safety of CXL for the treatment of progressive keratoconus”.

If you need a refresher, here is a previous rundown on cross-linking.

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.

Related Articles

Latest Posts